Sahni [23] showed reduced plasma PTPRM in patients with a poor prognosis of pancreatic ductal adenocarcinoma, suggesting that PTPRM could be used as a new blood-based biomarker to predict the prognosis of pancreatic ductal adenocarcinoma. The gene discussed is PTPRM; the disease is pancreatic ductal adenocarcinoma.